ATAI Investor Presentation Deck

SUMMARY OWNERSHIP 51.9%¹ PRODUCT PHARMA- COLOGY PRODUCT FEATURES INDICATIONS CURRENT STATUS INTELLECTUAL PROPERTY HIGHLIGHT (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1- pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salt oral capsules (RL-007) Cholinergic, glutamatergic and GABA-B receptor modulator No drug-related serious adverse events in over 500 study subject exposures, pro-cognitive effects demonstrated in two Phase 1 and two Phase 2 trials Primary: Cognitive Impairment Associated with Schizophrenia Potential: Autism, Alzheimer's dementia Phase 2a trial completed in H2'21 Issued composition of matter, formulation and method of use patents Previous Phase 2 showed pro-cognitive potential of RL-007 in 180 patients with diabetic peripheral neuropathic pain 22 RL-007 has previously shown pro-cognitive effects in human clinical studies "Symbol coding response is at a level that would correlate with better work/school performance" - Keith Nuechterlein EFFICACY DATA T-Scores (Normalized for age, gender, and education level) 10 5 O -5 4 COHORTS HVLT 31 Schizophrenia patients COMPLETED PHASE 2 POM TRIAL: Single-arm, single-blind dose-ranging clinical trial Symbol Coding 10mg 20mg 40mg ■80mg n=7 n=8 n=8 n=8 DAY -1 Category Fluency 1 RL-007 TID 2 Primary endpoint: Safety and tolerability 3 4 Improved Cohen's d* (Symbol Coding): 20 mg: 0.79 40 mg: 0.56 80 mg: 0.38 *Day 4 vs Day 2 Note: CIAS = Cognitive impairment associated with schizophrenia; RL-007 is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) (1) Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of June 30th, 2022. (2) Verbal learning was assessed by the "International Shopping List Task" (ISLT) (3) Verbal delayed recall was assessed by ISLT with a delayed recall, as a parameter for short-term memory FOLLOW-UP 8 Secondary endpoint: EEG-based biomarkers of cognition tartrate salt; TID denotes 3x/day dosing

View entire presentation